CSL

Today, we launched our FY26 full-year results. FY26 was a year of transition and setting a path to return to sustainable growth. To learn more about our results and how we’ve simplified the business and invested in our commercial capabilities, visit our Investor Centre: investors.csl.com #CSL

Today, we broke ground on a $1.5 billion investment to expand our plasma manufacturing capacity in Kankakee, Illinois.

Read how this will support the production of plasma-derived therapies and create new jobs in the US: newsroom.csl.com/2026-03-09-CSL…

#CSL #PlasmaDerivedTherapies #RareDisease

Today we announced our half‑year results. Read the full ASX announcement for details: bit.ly/4tzf89M #CSL

Today we’ve announced that Gordon Naylor has been appointed interim Chief Executive Officer and Managing Director, following Dr Paul McKenzie’s decision to retire. Read more: bit.ly/46DKj9K

Today, we announced an upcoming $1.5b in future U.S. capital investments, further strengthening our contribution to the U.S. healthcare ecosystem. This expansion builds on our significant U.S. presence and over $3b invested since 2018. This investment will generate hundreds of high-quality American jobs and substantially bolster U.S. manufacturing for critical plasma-derived therapies.

Our goal is to meet the growing clinical need for these life-saving medicines, which are often the sole effective treatments for many rare and serious diseases. We are proud to continue investing in American innovation and talent. newsroom.csl.com/2025-11-18-CSL…

#CSL #USManufacturing #PlasmaDerivedTherapies #HealthcareInnovation #AmericanJobs